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AbsTrACT
Objectives Ultrasound of temporal and axillary arteries 
may reveal vessel wall inflammation in patients with 
giant cell arteritis (GCa). We developed a ultrasound 
scoring system to quantify the extent of vascular 
inflammation and investigated its diagnostic accuracy 
and association with clinical factors in GCa.
Methods This is a prospective study including 89 
patients suspected of having GCa, of whom 58 had 
a confirmed clinical diagnosis of GCa after 6 months 
follow- up. all patients underwent bilateral ultrasound 
examination of the three temporal artery (Ta) segments 
and axillary arteries, prior to Ta biopsy. The extent of 
vascular inflammation was quantified by (1) counting 
the number of Ta segments and axillary arteries with a 
halo and (2) calculating a composite Halo score that also 
incorporated the thickness of each halo.
results Halo counts and Halo scores showed moderate 
diagnostic accuracy for a clinical diagnosis of GCa. They 
correlated positively with systemic inflammation. When 
compared with the halo count, the Halo score correlated 
better with C- reactive protein (CRP) levels and allowed 
to firmly establish the diagnosis of GCa in more patients. 
Higher halo counts and Halo scores were associated with 
a higher risk of ocular ischaemia. They allowed to identify 
subgroups of patients with low risk (≤5%) and high risk 
of ocular ischaemia (>30%).
Conclusions Ultrasound halo scoring allows to quantify 
the extent of vascular inflammation in GCa. extensive 
vascular inflammation on ultrasound may provide strong 
diagnostic confirmation and associates with ocular 
ischaemia in GCa.
InTrOduCTIOn
Giant cell arteritis (GCA) is an autoimmune disease 
characterised by inflammation of large- sized and 
medium- sized arteries. Ocular ischaemia is a 
feared complication of GCA.1 Laboratory testing 
often reveals systemic inflammation, that is, high 
C- reactive protein (CRP) levels, anaemia and 
thrombocytosis.2
EULAR recommendations identify temporal and 
axillary artery ultrasound as the first- line investiga-
tion in patients suspected of having GCA.3 A halo is 
the main ultrasound finding suggestive of GCA.4 5 
A halo is a homogeneous, hypoechoic wall thick-
ening of the artery, reflecting inflammation- induced 
oedema of the arterial wall.6 Ultrasound has a 77% 
sensitivity and 96% specificity for GCA.7
Little is known about the relationship between 
the extent of vascular inflammation on ultrasound 
and disease severity in GCA. Aschwanden et al 
evaluated 11 vascular regions for the presence 
of a halo and showed that involvement of large 
systemic arteries is associated with more weight 
loss.8 Schmidt et al linked axillary artery involve-
ment to a low risk of eye complications.9 The risk 
of eye complications was not related to the number 
of temporal artery (TA) segments with a halo in 
the latter study. In neither of these studies was halo 
thickness incorporated into the analysis of disease 
extent.
In the current study, we evaluated whether the 
extent of vascular inflammation on ultrasound 
could be linked to disease severity in GCA. To 
enumerate disease extent, we first calculated the 
number of TA segments and axillary arteries with 
Key messages
What is already known about this subject?
 ► Vascular ultrasound is the recommended first- 
line investigation in the diagnostic work- up of 
giant cell arteritis (GCA).
What does this study add?
 ► This prospective study shows that the extent 
of vascular inflammation on ultrasound, that 
is, a halo count ≥2 or Halo Score ≥3, identifies 
GCA patients at high risk for ocular ischaemia 
(>30%). Patients below these cut- off points 
have a low risk for ischaemic vision loss (≤5%). 
Furthermore, halo counts and Halo Scores 
associate with systemic inflammation.
 ► The presence of a high Halo Score ≥10 may help 
to firmly diagnose GCA in a substantial portion 
of patients, that is, with high specificity (>95%) 
and a high positive likelihood ratio (>5.0).
How might this impact on clinical practice or 
future developments?
 ► Quantifying the extent of vascular inflammation 
by ultrasound has diagnostic value and may 
help to discriminate between patients with a 
high or low risk for ocular ischaemia.
 ► The halo count and Halo Score await further 
validation and could potentially be interesting 
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a halo sign. Furthermore, we developed a novel Halo Score that 
encompassed both the number of halos and the maximum halo 
thickness in each vascular region. We investigated the diagnostic 
accuracy of halo counts and Halo Scores, and their relation-




Consecutive patients suspected of having GCA (n=104) were 
prospectively recruited at the Rheumatology Department of 
Southend University Hospital between June 2010 and December 
2013 as part of the TABUL study.10 Patients underwent arterial 
ultrasound followed by a TA biopsy (TAB). Ultrasound and TAB 
were performed within 7 days after initiation of high- dose gluco-
corticoids. Patients were re- assessed after 6 months. The refer-
ence standard for GCA was the final clinical diagnosis after 6 
months (online supplementary methods).
ultrasound
Ultrasound scans were performed by a single, experienced ultra-
sonographer (BD) with an Esaote MyLab70 or MyLabTwice. A 
linear probe (LA435) with a grey- scale frequency of 18 MHz 
and colour Doppler frequency of 9 MHz was used. The focus 
was positioned at 5 mm below the skin for the TA. The pulse 
repetition frequency was 2–3 kHz. The colour box was set at 
an angle of at least 60°. The gain setting was adjusted to just fill 
the lumen. Patients were lying in a (semi- )recumbent position 
during the examination. The common superficial TA, its parietal 
and frontal branches, as well as the axillary arteries were fully 
and bilaterally examined in the long and short planes. In each 
vascular territory, the thickness of the largest halo was measured 
with one decimal place at the point of maximum thickness in 
the longitudinal plane. The ultrasonographer was not blinded to 
the clinical data of the patient. An ultrasound expert panel eval-
uated all scans and reports to monitor the scan quality and the 
adequacy of the reported findings. A halo sign was morphologi-
cally defined as an ultrasound finding of a dark hypoechoic area 
around the vessel lumen. A composite Halo Score was developed 
based on percentiles of halo thickness in patients with GCA.
statistics
Information regarding statistics is provided in the figure legends 
and online supplementary methods. P values <0.05 were consid-
ered statistically significant. Data were analysed with IBM SPSS 
Statistics V.25, StatsDirect V.3.1.22 and Graphpad Prism V.5.
resulTs
Patient characteristics
Out of 104 patients with suspected GCA, 92 
patients underwent both ultrasound and TAB at baseline, and 
89 patients completed 6 months follow- up (table 1). A clinical 
diagnosis of GCA was established in 58 out of 89 patients. Diag-
noses in non- GCA patients are shown in online supplementary 
table S1.
Halo thickness and construction of the Halo score
At baseline, the three TA segments and the axillary artery 
were examined by ultrasound on each side. In GCA patients, 
halos were reported in 41 common TA segments, 29 parietal 
TA segments, 32 frontal TA segments and 14 axillary arteries 
(figure 1A). If present, the maximum thickness of the halo was 
measured (figure 1B).
In order to develop a composite Halo Score, we identified 
the 20%, 40%, 60% and 80% percentiles of the maximum halo 
thickness in the TA segments and axillary arteries of patients with 
GCA (online supplementary table S2). Based on these arbitrary 
percentiles, we assigned halo grade scores to each TA segment 
and axillary artery (figure 1C). The distribution of halo grades 
among GCA patients with a halo is shown in online supplemen-
tary tables S3 and S4.
The sum of all halo grade scores was used to construct the 
Halo Score for each patient (figure 1D). To give equal weight 
to temporal and axillary arteries, the halo grade scores of the 
axillary arteries were multiplied by a factor of 3. Therefore, the 
Halo Score values could range from 0 to 48. For halo counts in 
TA segments and axillary arteries, no correction factor was used 
for the axillary artery. Thus, halo counts could vary from 0 to 8.
diagnostic accuracy for GCA
Baseline halo counts and Halo Scores were higher in patients 
with a subsequently confirmed diagnosis of GCA than patients 
without GCA (figure 2A,B). Two non- GCA patients showed a 
high halo count. These halos were small in one male patient 
and could be attributed to atherosclerosis in one female patient 
(online supplementary table S5). Halo counts and Halo Scores 
showed similar diagnostic accuracy for a clinical diagnosis of 
GCA, as indicated by an area under the curve (AUC) of >0.70 
in the receiver operating characteristic (ROC) curve analysis 
(figure 2C,D). At the optimal cut- off point, the sensitivity/speci-
ficity and likelihood ratios were comparable for both ultrasound 
parameters. In a subanalysis restricted to halo counts/Halo 
Scores in the TA only, similar diagnostic accuracy was obtained 
(online supplementary table S6).
Alternative cut- off points providing a specificity of 95% for 
a clinical diagnosis of GCA could be obtained: a halo count of 
≥6, or Halo Score of ≥10. Although a Halo Score of ≥10 was 
present in 12 patients (21% of all patients with GCA), only two 
patients (3% of all patients with GCA) showed a halo count of 
≥6 (online supplementary table S7). The positive likelihood 
ratio of a Halo Score ≥10 was high (LR +6.41), but poor for 
the halo count at this cut- off point (LR +1.07). Thus, the Halo 
Score could be used more effectively than the halo count to 
establish a diagnosis of GCA in more patients.
diagnostic accuracy for positive TAb
The frequency and thickness of halos was higher in GCA patients 
with a positive TAB than patients with a negative TAB (online 
supplementary table S8). Consequently, halo counts and Halo 
Scores were higher in patients with a positive TAB than those 
with a negative biopsy (figure 2E,F). Both ultrasound param-
eters showed a good ability to predict a positive TABwith an 
AUC >0.80 in the ROC analysis (figure 2G,H). The sensitivity 
and specificity, positive likelihood ratios>2 and negative likeli-
hood ratios<0.5 indicated that halo counts and Halo Score may 
help to predict the TAB result. Comparable diagnostic accuracy 
was obtained, if only TAs halo counts were taken into account 
(online supplementary table S6).
effect of glucocorticoid treatment
Halo signs may disappear within days to weeks following initi-
ation of glucocorticoid treatment.5 11 When comparing patients 
with GCA receiving glucocorticoids for 0–1 days, 2–3 days and 
4–7 days prior to ultrasound, we did not observe any differences 
in halo counts or Halo Scores (online supplementary figure S1). 
Patients using glucocorticoids for 4–7 days prior to ultrasound 
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Table 1 Patients’ characteristics
Patients’ characteristics All patients (n=89) Patients with GCA (n=58) Patients without GCA (n=31)
Sex, no. of males 26 (29%) 15 (26%) 11 (36%)
Age, median (range) years 73 (44–96) 74 (50–96) 67 (44–90)
High- dose steroids started ≤7 days before baseline, no. of patients 75 (84%) 49 (85%) 26 (84%)
TAB positive according to pathologist, no. of patients 26 (29%) 26 (45%) 0 (0%)
TAB length, median (range) mm 7 (2–20) 7 (2–20) 8 (2–13)
Fulfilling 1990 ACR criteria for GCA, no of patients 72 (81%) 50 (86%) 22 (71%)
Any head pain present, no of patients 85 (96%) 55 (95%) 30 (97%)
New localised head pain, no of patients 77 (87%) 48 (83%) 29 (94%)
New generalised scalp tenderness, no of patients 52 (58%) 35 (60%) 17 (55%)
Swelling over temporal artery, no of patients 22 (25%) 14 (24%) 8 (26%)
Pain over temporal artery, no of patients 49 (55%) 29 (50%) 20 (65%)
Jaw claudication, no of patients 42 (47%) 32 (55%) 10 (32%)
Tongue claudication, no of patients 3 (3%) 2 (3%) 1 (3%)
Any visual symptoms, no of patients 47 (53%) 30 (52%) 17 (55%)
Reduced or lost vision, no of patients 38 (43%) 26 (45%) 12 (39%)
Double vision, no of patients 9 (10%) 4 (7%) 5 (16%)
Amaurosis fugax, no of patients 2 (2%) 2 (3%) 0 (0%)
Anorexia, no of patients 31 (35%) 22 (38%) 9 (29%)
Fatigue, no of patients 65 (73%) 42 (72%) 23 (74%)
Fever or night sweats, no of patients 38 (43%) 25 (43%) 13 (42%)
Polymyalgia, no of patients 16 (18%) 14 (24%) 2 (7%)
Temporal artery thickening, no of patients 28 (32%) 21 (36%) 7 (23%)
Temporal artery tenderness, no of patients 50 (56%) 29 (50%) 21 (68%)
Temporal artery abnormal pulse, no of patients 18 (20%) 16 (28%) 2 (7%)
Axillary artery tenderness, no of patients 8 (9%) 5 (9%) 3 (10%)
AION*, no of patients 15 (17%) 10 (17%) 5 (16%)
PION*, no of patients 5 (6%) 2 (3%) 3 (10%)
RAPD*, no of patients 7 (8%) 5 (9%) 2 (7%)
Ocular ischaemia (AION/PION/RAPD), no of patients 19 (21%) 12 (21%) 7 (23%)
Ocular palsy*†, no of patients 0 (0%) 0 (0%) 0 (0%)
Bruits*, no of patients 0 (0%) 0 (0%) 0 (0%)
Stroke* 2 (2%) 0 (0%) 2 (7%)
ESR, mm/hour,† median (range) 34 (3–90) 44 (3–90) 9 (3–77)
CRP, mg/L,† median (range) 46 (3–329) 54 (3–329) 13 (3–205)
Haemoglobin (g/dL), median (range) 12.8 (8.9–16.0) 12.0 (8.9–15.5) 13.5 (10.1–16.0)
Platelets, 109/L, median (range) 343 (126–661) 363 (167–661) 317 (126–522)
Details of the 89 patients recruited in the TABUL study at Southend University Hospital, who underwent ultrasound, temporal artery biopsy and 6 months follow- up.
ESR was determined in n=57 patients and CRP in n=54 subjects. ESR and CRP were measured before initiation of high- dose glucocorticoid treatment. Haemoglobin levels and platelet counts were determined 
prior to high- dose glucocorticoid treatment or within 7 days after initiation of this treatment.
*Considered negative if not reported.
†ESR and CRP were not performed in every subject.
AION, anterior ischaemic optic neuropathy;CRP, C- reactive protein; ESR, erythrocyte sedimentation rate; GCA, giant cell arteritis; PION, posterior ischaemic optic neuropathy; RAPD, relative afferent pupillary 
defect; TAB, temporal artery biopsy.
tended to have a higher prevalence of ocular ischaemia and poly-
myalgic symptoms when compared with other patients, although 
not statistically significant (online supplementary table S9).
Vascular and systemic inflammation
We questioned if ultrasound findings could be linked to systemic 
inflammation in patients with GCA. Halo counts showed no 
correlation with haemoglobin levels but correlated positively 
with CRP levels and platelet counts (figure 3A). The Halo 
Score correlated even better with CRP levels, showed a positive 
correlation with platelets counts, and correlated negatively with 
haemoglobin levels (figure 3B). In a subanalysis of halo counts/
Halo Scores restricted to the TA only, these correlations became 
less clear (online supplementary table S10). The presence of 
axillary artery involvement tended to be associated with more 
systemic inflammation (online supplementary table S11). Taken 
together, Halo Scores associated stronger with systemic inflam-
mation than halo counts.
The erythrocyte sedimentation rate (ESR), as measured by a 
capillary photometric- kinetic technique (Alifax),12 was remark-
ably low in patients with GCA (online supplementary table S12). 
Pretreatment ESR was <30 mm/hour in 31% of GCA patients, 
while CRP was <10 mg/L in 2% of patients. Only 46% of GCA 
patients showed an ESR >50 mm/hour. Thus, the ESR showed 
no correlation with CRP levels, halo counts or Halo Scores 
(online supplementary figure S2).
extent of vascular inflammation and patients’ characteristics
We performed multiple linear regression analysis to investigate 
if ocular ischaemia, or perhaps other clinical characteristics, 
were associated with higher halo counts or Halo Scores. Ocular 
ischaemia was defined by the presence of anterior ischaemic 
optic neuropathy (AION), posterior ischaemic optic neuropathy 
(PION) and/or a relative afferent pupillary defect (RAPD). Both 
ocular ischaemia and male sex were independently associated 
with higher halo counts and Halo Scores in patients with GCA 
copyright.
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Figure 1 Ultrasound halo scoring. (A) Representative ultrasound images of halo signs, and measurements of halo thickness, in the common 
superficial TA, parietal TA, frontal TA and axillary artery. (B) Thickness of halo signs that were reported in 41 common TA segments, 29 parietal TA 
segments, 32 frontal TA segments and 14 axillary arteries of patients with GCA. (C) Halo grade scoring system and cut- off values. Due to similar 40% 
and 60% percentile boundaries in the parietal TA, a cut- off value of 0.5 mm was used for a grade 3 halo in this TA segment. (D) Construction of the 
Halo Score. Axillary artery scores were multiplied by 3 to give equal weight to the TA and axillary artery for the Halo Score. TA, temporal artery.
(table 2). No further relationships were observed between clin-
ical features and ultrasound parameters.
diagnostic accuracy for ocular ischaemia
Halo counts and Halo Scores showed fair ability to discriminate 
between GCA patients with and without ocular ischaemia, as 
indicated by an AUC >0.70 in the ROC analysis (figure 4A). 
At the optimal cut- off point for ocular ischaemia, that is, halo 
count ≥2 or Halo Score ≥3, an excellent sensitivity and poor 
specificity were obtained. At the optimal cut- off points, positive 
likelihood ratios <2 indicated that halo counts and Halo Scores 
were not helpful in predicting the presence of ocular ischaemia. 
However, negative likelihood ratios were <0.2. Thus, low halo 
counts and Halo Scores helped to identify a substantial group 
of patients with a low risk of ocular ischaemia (figure 4B). In a 
subanalysis of halo counts and Halo Scores restricted to the TA 
only, comparable diagnostic accuracy for ocular ischaemia was 
obtained (online supplementary figure S3). The presence of axil-
lary involvement per se showed no effect on the risk of ocular 
ischaemia (online supplementary table S13).
Next, we evaluated if halo counts and Halo Scores were indepen-
dent predictors for ocular ischaemia in a logistic regression analysis 
(online supplementary table S14). A halo count ≥2 provided an 
OR for ocular ischaemia of 12.000 (95% CI=1.430 to 100.705; 
p=0.022), whereas a Halo Score ≥3 showed an OR of 9.880 
(95% CI=1.137 to 85.887; p=0.038). Other clinical character-
istics were not predictive of ocular ischaemia. Thus, halo counts 
and Halo Scores were independent predictors of ocular ischaemia.
dIsCussIOn
We show that the extent of vascular inflammation on ultrasound, 
as quantified by the halo count and novel Halo Score, can be 
linked to ocular ischaemia and systemic inflammation in GCA. 
The Halo Score allowed to firmly establish a diagnosis of GCA 
in more patients than the halo count.
The extent of inflammation was measured in the three TA 
segments and axillary arteries. Subclavian and facial arteries were 
not evaluated. However, axillary artery involvement identifies 
the vast majority of patients with inflammation of large systemic 
arteries,13 whereas TA involvement identifies nearly all patients 
with cranial artery involvement.14 EULAR recommendations 
recognise temporal and axillary artery ultrasound as the first- 
line investigation in GCA.3 Examination of temporal and axillary 
arteries might therefore provide a reasonable estimation of disease 
extent in GCA.
Extensive vascular inflammation identified GCA patients 
at high (>30%) risk of ocular ischaemia. However, half of 
patients showed low halo counts/Halo Scores and a ≤5% risk 
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Figure 2 Diagnostic accuracy of halo count and Halo Score for GCA. (A) Baseline halo count in common superficial TAs, parietal TAs, frontal TAs and 
axillary arteries and (B) Halo Scores in patients with an eventually confirmed clinical diagnosis of GCA (n=58) versus non- GCA patients (n=31). (C) 
ROC curve showing the diagnostic accuracy of baseline halo counts and (D) Halo Scores for an eventual clinical diagnosis of GCA after 6 months. The 
optimal cut- off points were determined by Youden index. (E) Baseline halo counts and (F) Halo Scores in patients with a positive TAB (n=26) versus 
patients with a negative TAB (n=63). Overall, 25 TABs showed transmural inflammation and/or giant cells. One TAB considered positive for GCA 
showed an adventitial infiltrate, elastic lamina disruption and intimal hyperplasia without transmural inflammation/giant cells. (G) ROC curve showing 
the diagnostic accuracy of halo counts and (H) Halo Scores for a positive TAB. The optimal cut- off point was determined by Youden index. AUC, area 
under the curve; LR+, positive likelihood ratio; LR−, negative likelihood ratio; ROC, receiver operating characteristic; Sens, sensitivity; Spec, specificity; 
TA, temporal artery; TAB, temporal artery biopsy. Statistical significance at (A, B, E, F) was tested by Mann- Whitney U test: **p<0.01, ***p<0.001.
Figure 3 Relationship of halo count and Halo Score with systemic inflammation. (A) Correlation of halo counts and (B) Halo Scores with CRP, 
haemoglobin and platelets in patients with a clinical diagnosis of GCA. CRP levels were determined prior to initiation of treatment in 41 GCA patients. 
Haemoglobin levels and platelet counts were measured prior to treatment or within 7 days after initiation of high- dose glucocorticoids in 58 GCA 
patients. Correlations were determined by Spearman’s rank correlation coefficient.
of GCA- related vision loss. As visual symptoms described by 
patients are not always related to GCA, we strictly defined 
ocular ischaemia by the presence of AION, PION and/or RAPD. 
Patients with suggestive eye symptoms were referred to the 
ophthalmologist in this single hospital study. Nevertheless, it 
might be a bias that not every patient underwent ophthalmolog-
ical examination. Previously, no relationship was noted between 
the number of TA segments with a halo and ocular complica-
tions.9 However, the definition of ocular complications in the 
latter study was broader than in the current study. Wall thick-
ening of arteries supplying the retina is thought to cause ocular 
ischaemia in GCA.1 15 Our findings indicate that wall thickening 
in the latter arteries likely parallels that in other arteries in GCA.
The extent of vascular inflammation correlated well with 
systemic inflammation in patients with GCA. Halo counts 
correlated positively with CRP levels and platelets counts. Halo 
Scores correlated even better with CRP levels than halo counts 
and also showed an inverse correlation with haemoglobin levels. 
No association was found with the ESR, which was measured by 
a capillary photometric–kinetic technique. This method provides 
an indirect estimation of the ESR12 and might be less accurate 
than the traditional Westergren in the context of rheumatic 
inflammatory diseases.16 17 Overall, our findings suggest a link 
between arterial and systemic inflammation in GCA.
Halo counts and Halo Scores showed comparable diagnostic 
accuracy for a clinical diagnosis of GCA. At the optimal cut- off 
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Final model of multiple linear 
regression b (95% CI) P value
Halo count Age –
Sex 1.109 (0.172 to 2.047)* 0.021
Ocular ischaemia 1.103 (0.089 to 2.116)* 0.034
Polymyalgia –
Two or more systemic 
symptoms
–
Temporal artery palpable 
changes
–
Halo Score Age –
Sex 2.902 (0.100 to 6.984)† 0.041
Ocular ischaemia 3.488 (0.305 to 8.143)† 0.028
Polymyalgia 2.813 (−0.053 to 7.080)† 0.056
Two or more systemic 
symptoms
–
Temporal artery palpable 
changes
–
Data are shown for baseline halo count and Halo Scores in patients with GCA (n=58). Multiple 
linear regression analysis was performed with backward exclusion of predicting variables. Since 
the Halo Score was not normally distributed, the Halo Score was transformed by square root. 
The probability of F for removal was 0.10. Results of the final model are shown. Age in years. 
Sex: 0=female, 1=male. Ocular ischaemia (ie, anterior ischaemic optic neuropathy, posterior 
ischaemic optic neuropathy and/or relative afferent pupillary defect), polymyalgia, two or more 
systemic symptoms (ie, anorexia, fever/night sweats, fatigue), temporal artery palpable changes 
(ie, thickening and/or loss of pulse): 0=absent, 1=present. (−) Variable removed due to backward 
exclusion.
*R2=0.157, F(2,55) = 5.138, p=0.009.
†R2=0.207, F(3,54) = 4.688, p=0.006.
GCA, giant cell arteritis.
Figure 4 Halo count and Halo Score associated with ocular ischaemia. (A) Receiver operating characteristic curve showing diagnostic accuracy of 
baseline halo count (left panel) and Halo Score (right panel) for concomitant presence of ocular ischaemic symptoms. Ocular ischaemia was defined as 
the presence of anterior ischaemic optic neuropathy, posterior ischaemic optic neuropathy and/or a relative afferent pupillary defect. The optimal cut- 
off point was determined by Youden index. (B) Presence of ocular ischaemia (percentages are shown) among patients with low versus high halo count 
(left panel), or low versus high Halo Score (right panel) as determined by the optimal cut- off points mentioned at (A). AUC, area under the curve; HS, 
Halo Score; LR+, positive likelihood ratio; LR−, negative likelihood ratio; Sens, sensitivity; Spec, specificity.
points, both ultrasound parameters provided fair sensitivity (78%) 
but moderate specificity (55%–61%) for a diagnosis of GCA. 
Even better diagnostic accuracy was obtained for a positive TAB, 
which supports the idea that ultrasound might replace a TAB under 
certain conditions.3 Alternative cut- off points providing 95% spec-
ificity for a clinical diagnosis of GCA could also be obtained. Few 
patients with GCA fulfilled this cut- off point for the halo count. In 
contrast,>20% of patients with GCA showed Halo Scores above 
the 95% specificity cut- off point, that is, a score ≥10. At this cut- 
off point, a high positive likelihood ratio could be obtained for the 
Halo Score, which allowed us to make a confident diagnosis of 
GCA in a substantial portion of patients.
Male sex was associated with higher halo counts and Halo 
Scores in patients with GCA. Recently, male sex predicted the 
presence of a halo sign on ultrasound in patients with GCA.18 
It might be possible that GCA is associated with more arterial 
thickening in men than women. However, it is also conceivable 
that the arterial calibre and arterial wall thickness are in general 
higher in men than women.5 It would be interesting to collect 
sex- specific, normative data on arterial wall thickness.
A halo was morphologically defined as a dark hypoechoic 
area around the vessel lumen. As the halo compression sign 
was reported at the end of our study,19 this sign was not tested. 
Recently, diagnostic cut- off values have been described for the 
intima–media thickness in TAs, as measured by a 22 MHz trans-
ducer.20 Although still considered state of the art, our 18 MHz 
transducer frequently does not allow us to visualise the inti-
ma–media complex of the TAs. Halo thickness and intima–media 
thickness are therefore not fully interchangeable parameters. 
Halo counts and thickness might have been higher if measured 
with higher frequency transducers. In accordance with Monti 
et al,21 we observed relatively similar halo thickness among the 
three TA segments. Halo counts in the latter study were compa-
rable with those in the current study.
The same morphological halo definition was applied to the 
axillary arteries. The dark hypoechoic halo pattern differs from 
the normal intima–media complex, which can be readily identi-
fied as a double line in the axillary artery.6 Part of halos reported 
in the axillary artery were smaller than a recently proposed diag-
nostic cut- off value, that is, 1.0 mm.20 However, two provisional 
reports have suggested that axillary arteries may be inflamed 
despite a halo thickness <1.0 mm on ultrasound.22 23 Since halos 
<1.0 mm might still relate to disease activity, these halos were 
included in the halo count/Halo Score. Overall, our main study 
findings were not compromised by axillary artery involvement, 
as indicated by our subanalyses restricted to the TA only.
We observed no clear association between short- term gluco-
corticoid treatment and extent of vascular inflammation on 
ultrasound. Serial ultrasound examinations before and after initi-
ation of glucocorticoid treatment have shown that it takes weeks 
to months before the majority of TA halos disappear, while only 
few axillary artery halos disappear.5 11 24 In our study, lack of 
treatment effect may have two explanations. First, treatment 
duration might have been too short. Second, patients taking 
glucocorticoids for 4–7 days showed a slightly higher prevalence 
of symptoms associated with higher halo counts/Halo Score than 
patients with shorter treatment duration.
A strong point of our study is its prospective design with patients 
undergoing ultrasound and TAB according to a fixed protocol. 
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The clinical diagnosis was rigorously established after 6 months 
follow- up. Ultrasound was performed by an experienced ultraso-
nographer. Our study has also potential limitations. There was a 
bias towards cranial GCA. The ultrasonographer was not blinded 
to the clinical data. However, a symptom likely to bias the ultraso-
nographer, that is, an abnormal TA on palpation, showed no effect 
on halo counts or Halo Scores. The intra- rater and inter- rater reli-
abilities were not tested, and should be evaluated in future studies. 
Nevertheless, the quality of the ultrasound scans and reports was 
monitored by an expert panel. Our findings were derived from a 
post- hoc analysis of a diagnostic trial and obtained from a single 
centre.10 The Halo Score should be further validated by currently 
ongoing, prospective, multicentre studies ( ClinicalTrials. gov 
NCT03765788; and NIHR Portfolio study #264294), prior to 
application in the clinic.
In conclusion, the extent of arterial inflammation in GCA 
can be quantified by ultrasound halo scoring. A high volume of 
vascular inflammation on ultrasound might strongly support the 
diagnosis of GCA and identifies patients at risk for ocular isch-
aemia. The clinical application of halo counts and Halo Scores 
warrants further validation in other studies.
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